Effect of revaccination using different schemes among adults with low or undetectable anti-HBs titers after hepatitis B virus vaccination

Clinical and Vaccine Immunology

Volumn 17, Issue 10, 2010, Pages 1548-1551

  Lin, Chao Shuang ^a   Xie, Shi Bin ^a   Liu, Jing ^a   Zhao, Zhi Xin ^a   Chong, Yu Tian ^a   Gao, Zhi Liang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; RECOMBINANT HEPATITIS B VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; INJECTION SITE SWELLING; MALE; PRIORITY JOURNAL; PROPHYLAXIS;

ADOLESCENT; ADULT; CHINA; FEMALE; GENETIC VECTORS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; SACCHAROMYCES CEREVISIAE; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 77957877183     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00064-10     Document Type: Article

References (27)

1. Chiaramonte, M., T. Ngatchu, S. Majori, V. Baldo, M. E. Moschen, G. Renzulli, and R. Trivello. 1995. Response to an extra dose of hepatitis B vaccine and specific antibody persistence in non-responders to primary immunization. Scand. J. Gastroenterol. 30:601-603.
2. Clemens, R., R. Sänger, J. Kruppenbacher, W. Höbel, W. Stanbury, H. L. Bock, and W. Jilg. 1997. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule - results of a post-marketing surveillance. Vaccine 15:349-352.
3. Coates, T., R. Wilson, G. Patrick, F. André, and V. Watson. 2001. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin. Ther. 23:392-403.
4. Cruciani, M., C. Mengoli, G. Serpelloni, A. Lanza, M. Gomma, S. Nardi, C. Rimondo, F. Bricolo, S. Consolaro, M. Trevisan, and O. Bosco. 2009. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 27:17-22.
5. Desombere, I., T. Cao, Y. Gijbels, and G. Leroux-Roels. 2005. Non-responsiveness to hepatitis B surface antigen vaccines is not caused by defective antigen presentation or a lack of B7 co-stimulation. Clin. Exp. Immunol. 140:126-137.
6. Dourado, M., V. Alves, L. Mesquita, I. Ramos, A. M. Pinto, and M. S. Rosa. 2004. CD26/DPPIV and response to hepatitis B vaccination. Pathophysiology 11:147-152.
7. Ganczak, M., Z. Szych, and M. Korzeń. 2009. Preoperative vaccination for HBV at Polish hospitals as a possible public health tool to limit the spread of the epidemic: a cross-sectional study. Vaccine 27:3969-3974.
8. Ghebrehewet, S., D. Baxter, M. Falconer, and K. Paver. 2008. Intradermal recombinant hepatitis B vaccination (IDRV) for non-responsive healthcare workers (HCWs). Hum. Vaccine 4:280-285.
9. Guo, Y., D. Ren, X. He, F. Wang, L. Jiang, S. Song, Y. He, and S. Sun. 2009. A novel mouse model for immunogenic evaluation of human HBV vaccines. Vaccine 27:5692-5699.
10. Huang, M. L., W. L. Liao, and M. S. Ho. 2007. HBV serological markers of vaccinated children in remote areas of Taiwan: emphasis on factors contributing to vaccine failure. Vaccine 25:6326-6333.
11. Jack, A. D., A. J. Hall, N. Maine, M. Mendy, and H. C. Whittle. 1999. What level of hepatitis B antibody is protective? J. Infect. Dis. 179:489-492.
12. Liu, R., Q. Lin, Y. Sun, X. Lu, Y. Qiu, Y. Li, and X. Guo. 2009. Expression, purification, and characterization of hepatitis B virus surface antigens (HBsAg) in yeast Pichia pastoris. Appl. Biochem. Biotechnol. 158:432-444.
13. Mast, E. E., H. S. Margolis, A. E. Fiore, E. W. Brink, S. T. Goldstein, S. A. Wang, L. A. Moyer, B. P. Bell, and M. J. Alter. 2005. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR Recommend. Rep. 54(RR-16):1-23.
14. Mizrahi, M., G. Lalazar, A. Ben Ya'acov, D. M. Livovsky, Y. Horowitz, L. Zolotarov, R. Adler, D. Shouval, and Y. Ilan. 2008. β- Glycoglycosphingolipid-induced augmentation of the anti-HBV immune response is associated with altered CD8 and NKT lymphocyte distribution: a novel adjuvant for HBV vaccination. Vaccine 26:2589-2595.
15. Nyström, J., K. Cardell, T. B. Björnsdottir, A. Fryden, C. Hultgren, and M. Sällberg. 2008. Improved cell mediated immune responses after successful re-vaccination of non-responders to the hepatitis B virus surface antigen (HBsAg) vaccine using the combined hepatitis A and B vaccine. Vaccine 26:5967-5972.
16. Rapicetta, M., E. D'Ugo, C. Argentini, S. Catone, A. Canitano, R. Giuseppetti, and R. Gluck. 2009. New perspectives for hepatitis B vaccines and immunization. Vaccine 27:3271-3275.
17. Rendi-Wagner, P., M. Kundi, H. Stemberger, G. Wiedermann, H. Holzmann, M. Hofer, K. Wiesinger, and H. Kollaritsch. 2001. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 19:2055-2060.
18. Shivananda, V. Somani, B. S. Srikanth, M. Mohan, and P. S. Kulkarni. 2006. Comparison of two hepatitis B vaccines (GeneVac-B and Engerix-B) in healthy infants in India. Clin. Vaccine Immunol. 13:661-664.
19. Struve, J., B. Aronsson, B. Frenning, M. Forsgren, and O. Weiland. 1994. Seroconversion after additional vaccine doses to non-responders of three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine. Scand. J. Infect. Dis. 26:468-470.
20. van der Sande, M. A., M. Mendy, P. Waight, C. Doherty, S. J. McConkey, A. J. Hall, and H. C. Whittle. 2007. Similar long-term vaccine efficacy of two versus three doses of HBV vaccine in early life. Vaccine 25:1509-1512.
21. Vellanki, R. N., N. Komaravelli, R. Tatineni, and L. N. Mangamoori. 2007. Expression of hepatitis B surface antigen in Saccharomyces cerevisiae utilizing glyceraldeyhyde-3-phosphate dehydrogenase promoter of Pichia pastoris. Biotechnol. Lett. 29:313-318.
22. Velu, V., S. Nandakumar, S. Shanmugam, S. S. Jadhav, P. S. Kulkarni, and S. P. Thyagarajan. 2007. Comparison of three different recombinant hepatitis B vaccines: GeneVac-B, Engerix B and Shanvac B in high risk infants born to HBsAg positive mothers in India. World J. Gastroenterol. 13:3084-3089.
23. Whittle, H., S. Jaffar, M. Wansbrough, M. Mendy, U. Dumpis, A. Collinson, and A. Hall. 2002. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 325:569.
24. Zhang, W., X. Du, G. Zhao, H. Jin, Y. Kang, C. Xiao, M. Liu, and B. Wang. 2009. Levamisole is a potential facilitator for the activation of Th1 responses of the subunit HBV vaccination. Vaccine 27:4938-4946.
25. Zhang, Y., W. Jiang, Y. Fan, J. Wen, W. Hao, and M. Qian. 2008. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant. J. Virol. Methods 153:142-148.
26. Zhuang, G. H., H. Yan, and X. L. Wang. 2006. Risk factors of and mechanism for non-responsiveness to hepatitis B vaccination. Zhonghua Gan Zang Bing Za Zhi 14:157-160.
27. Zhuang, G. H., H. Yan, X. L. Wang, L. Y. Hwang, Q. Wu, L. R. Wang, and H. Y. Gao. 2006. Hepatitis B revaccination in healthy non-responder Chinese children: five-year follow-up of immune response and immunologic memory. Vaccine 24:2186-2192.